Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD)
Abstract
Prevention of levodopa-induced dyskinesias is a therapeutic challenge for physicians
Striatal Mechanisms of Levodopa-Induced Dyskinesia
The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson's
Dystonia arises most often spontaneously, although it may be seen after stroke, injury, or as a result of genetic causes
Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to
This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management
Because dyskinesias tend to occur at peak concentrations of levodopa, one management strategy is to reduce dopamine levels
Current evidence indicates that dyskinesias develop in response to pulsatile stimulation of striatal dopamine receptors
l-dopa-induced nausea
At present, it seems only possible to delay dyskinesias and motor fluctuations
Levodopa-induced dyskinesia (LID) is a common complication after dopamine-replacement therapy in Parkinson's disease
l -dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons
S
Using objective LID quantification, we compared the median time to onset of LID in subjects taking concomitant DHA or placebo